The academic-entrepreneur model built companies and minted millionaires. What happens when one of its earliest advocates quits?
CAMBRIDGE, Mass. — For years in a small handful of US research and venture capital hot spots, a careful balance has brought prestige and wealth to universities, academics and investors.
From inside their labs, professors could found a company and turn their work into a drug, marrying academic prestige with practical application. Stuart Schreiber helped cement that blueprint when he co-founded the Broad Institute of Harvard and MIT in 2003. Since then, it’s become a global genomics powerhouse, churned out breakthrough academic work, and seen its researchers launch scores of biotech startups.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
